Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00101452 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

A NA study of Depression, sponsored by Maurizio Fava, MD.

Completed
Registry status
NA
Development phase
199
Enrollment target
2
Study locations

NCT00101452: Completed NA study of Depression, sponsored by Maurizio Fava, MD.

NCT00101452 is a NA study of Depression that has completed, run by Maurizio Fava, MD. The registered enrollment target is 199 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00101452, a NA study of Depression, has completed, sponsored by Maurizio Fava, MD.

COMPLETED
Registry status
NA
Development phase
199 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.

Primary Outcome

The change in total HAM-D score between baseline and endpoint was the primary outcomes measure. This measure is a clinician rated inventory of depressive symptoms. All items are scored on a scale of zero to four and the sum of the scores provides the total score for the measure. Scores can range from 0- 68. On this scale, higher scores indicate poorer outcomes.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Escitalopram
  • DRUG S-adenosyl-l-methionine

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Rhode Island

  • Butler Hospital - Providence

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 2005-04
Est. Completion 2010-06
Phase NA
Maurizio Fava, MD

4 total trials

What the finished NCT00101452 record still lists

NCT00101452 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00101452 reports a single indexed study location in Massachusetts, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00101452 about?

NCT00101452 is a clinical study titled "Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression". The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.

What is the current status of trial NCT00101452?

This trial is currently completed. It is a NA study. The enrollment target is 199 participants. The study started on 2005-04. Estimated completion is 2010-06.

What conditions does trial NCT00101452 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00101452?

The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), S-adenosyl-l-methionine (DRUG).

Who is sponsoring clinical trial NCT00101452?

This trial is sponsored by Maurizio Fava, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00101452 being conducted?

This trial has 2 study locations across Massachusetts, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00101452's enrollment target sits among peer trials

199 216th of 679 higher than 464 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04312126 · 199 participants

    The Beneficial Effects of Naps on Motor Learning

  • NCT04951622 · 199 participants · Phase 3

    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  • NCT06474533 · 199 participants

    Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00101452, the US trial registry maintained by the National Library of Medicine. NCT00101452 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.